This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChronic Myeloid Leukemia Treatments · Chronic Lymphocytic Leukemia Research · Lymphoma Diagnosis and Treatment
Following the publication of this article, concerns were raised regarding Figure 1. Specifically:
The lanes within this panel appear similar to Figure 1B of [3] where lane conditions are described differently to the respective lanes in [1].
The corresponding author stated the original underlying data were no longer available for editorial review. In the absence of original underlying data, these concerns cannot be resolved.
In light of the concerns affecting multiple panels in Figure 1 that question the integrity and reliability of these data, the PLOS ONE Editors retract this article.
ZI and AA did not agree with the retraction. MI, MIN, AG, AST, AQ, NuR, AMK, HIS, MK, RH, MK, SMB, AJ, MNA, MA, AM, MR, and TA either did not respond directly or could not be reached.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, et al. (2013) Sensitive Detection of Pre-Existing BCR-ABL Kinase Domain Mutations in CD 34+ Cells of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients Is Associated with Imatinib Resistance: Implications in the Post-Imatinib Era. P Lo S ONE 8(2): e 55717. doi: 10.1371/journal.pone.0055717 23409026 PMC 3568121 · doi ↗ · pubmed ↗
- 2Iqbal Z., Siddiqui R.T. & Qureshi J.A. Two different point mutations in ABL gene ATP-binding domain conferring primary imatinib resistance in a chronic myeloid leukemia (CML) patient: A case report. Biol. Proced. Online 6, 144–148 (2004). 10.1251/bpo 83 15243647 PMC 443563 · doi ↗ · pubmed ↗
- 3Taj A., Khalid M., Qayyum A. et al. Detection of BCR-ABL kinase domain mutations in CD 34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance. Nat Prec (2011). 10.1038/npre.2011.6645.1 · doi ↗
